Brainsway Dtms denied as not medically necessary by Humana?

Humana's specific coverage criteria for brainsway dtms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny BrainsWay Deep TMS for Medical Necessity

A medical-necessity denial from Humana means the plan reviewed the submitted clinical information and concluded that the treatment does not meet its criteria for being necessary, appropriate, and consistent with evidence-based standards for the diagnosed condition. For BrainsWay Deep TMS, this often occurs when the prior-authorization submission is missing documentation of failed prior treatments, lacks a clinical severity assessment, or does not clearly connect the patient's presentation to Humana's published coverage criteria.

These denials are frequently overturned on appeal when the full clinical picture is properly documented and submitted.

## Federal Appeal Framework

• ACA §2719 / External Review: Available for most non-grandfathered plans. You have approximately 4 months (180 days) from the denial date to request independent external review. Expedited review (typically 72 hours) applies when your health situation is urgent.
• ERISA §503 (employer-sponsored plans): Guarantees a full-and-fair review, written denial rationale citing specific criteria, and the right to submit additional evidence.

## Appeal Process and Timeline

1. Request the full denial file — the denial letter must cite the specific criteria not met. If it does not, request this in writing. 2. Internal appeal — submit a comprehensive response with all supporting documentation. Humana typically has 30 days to decide (72 hours for urgent/expedited). 3. External review — if the internal appeal is denied, an independent reviewer will evaluate using objective clinical standards, not solely Humana's internal policy.

## Documentation to Gather

• Diagnosis confirmation: Comprehensive chart notes, diagnostic coding, and any validated clinical assessments establishing the diagnosis and its severity.
• Prior treatment history: A complete list of all treatments previously tried for this condition—including medication trials, psychotherapy, and any other interventions—with start and end dates and documented outcomes or reasons for discontinuation.
• Clinical severity documentation: Validated rating scales, functional-impairment notes, and clinician assessments from the chart showing the degree to which the condition affects the patient's daily functioning.
• Prescriber medical-necessity letter: A detailed letter addressing each of Humana's published criteria for Deep TMS coverage, mapping the patient's clinical facts to each requirement.
• FDA clearance: Confirmation that BrainsWay Deep TMS is FDA-cleared for the specific indication being treated.

## Criteria-Mapping Structure

Obtain Humana's current published coverage/medical policy for Deep TMS and the FDA-approved labeling for BrainsWay. For each policy criterion, document the corresponding chart evidence:

| Humana Coverage Criterion | Documented Evidence | |---|---| | Confirmed diagnosis (per policy definition) | [Specific chart documentation] | | Number/type of prior treatment failures | [Treatment list with dates and outcomes] | | Severity threshold met | [Rating scale scores and clinical notes] | | Prescriber qualifications | [Provider specialty and credentials] | | Absence of contraindicated conditions (per policy) | [Relevant clinical notes] |

Do not rely on general descriptions. Each criterion should be answered with a specific, dated chart entry.